25 XP   0   0   10

InBioGen Co Ltd
Buy, Hold or Sell?

Let's analyse Inbiogen together

PenkeI guess you are interested in InBioGen Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of InBioGen Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about InBioGen Co Ltd

I send you an email if I find something interesting about InBioGen Co Ltd.

Quick analysis of Inbiogen (30 sec.)










What can you expect buying and holding a share of Inbiogen? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩14,891.16
Expected worth in 1 year
₩29,035.59
How sure are you?
37.9%

+ What do you gain per year?

Total Gains per Share
₩14,144.43
Return On Investment
151.4%

For what price can you sell your share?

Current Price per Share
₩9,340.00
Expected price per share
₩9,340 - ₩9,340
How sure are you?
50%

1. Valuation of Inbiogen (5 min.)




Live pricePrice per Share (EOD)

₩9,340.00

Intrinsic Value Per Share

₩2,830.56 - ₩3,471.00

Total Value Per Share

₩17,721.73 - ₩18,362.16

2. Growth of Inbiogen (5 min.)




Is Inbiogen growing?

Current yearPrevious yearGrowGrow %
How rich?$104m$60.4m$38.5m38.9%

How much money is Inbiogen making?

Current yearPrevious yearGrowGrow %
Making money$3.2m-$17.9m$21.2m644.8%
Net Profit Margin221.9%-782.5%--

How much money comes from the company's main activities?

3. Financial Health of Inbiogen (5 min.)




4. Comparing to competitors in the Footwear & Accessories industry (5 min.)




  Industry Rankings (Footwear & Accessories)  


Richest
#55 / 105

Most Revenue
#104 / 105

Most Profit
#47 / 105

What can you expect buying and holding a share of Inbiogen? (5 min.)

Welcome investor! Inbiogen's management wants to use your money to grow the business. In return you get a share of Inbiogen.

What can you expect buying and holding a share of Inbiogen?

First you should know what it really means to hold a share of Inbiogen. And how you can make/lose money.

Speculation

The Price per Share of Inbiogen is ₩9,340. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Inbiogen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Inbiogen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩14,891.16. Based on the TTM, the Book Value Change Per Share is ₩3,536.11 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-663.61 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Inbiogen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.040.0%0.080.0%-0.430.0%-0.050.0%-0.030.0%
Usd Book Value Change Per Share-0.020.0%2.480.0%-0.460.0%0.490.0%0.360.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.020.0%2.480.0%-0.460.0%0.490.0%0.360.0%
Usd Price Per Share6.54-3.28-0.06-0.75-0.55-
Price to Earnings Ratio-41.45--3.07--0.02--0.64--2.02-
Price-to-Total Gains Ratio-267.48--66.70--0.21--14.16--13.58-
Price to Book Ratio0.63-0.32-0.06-0.60-0.50-
Price-to-Total Gains Ratio-267.48--66.70--0.21--14.16--13.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.538
Number of shares152
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.480.49
Usd Total Gains Per Share2.480.49
Gains per Quarter (152 shares)376.2474.12
Gains per Year (152 shares)1,504.97296.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10150514950296286
20301030000593582
30451545050889878
4060206010011861174
5075257515014821470
6090309020017791766
701053510525020752062
801204012030023722358
901354513535026682654
1001505015040029652950

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%6.06.00.050.0%8.012.00.040.0%9.020.00.031.0%9.020.00.031.0%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%11.018.00.037.9%11.018.00.037.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%11.018.00.037.9%11.018.00.037.9%

Fundamentals of Inbiogen

About InBioGen Co Ltd

INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses. The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-15 17:06:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of InBioGen Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Inbiogen earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Inbiogen to the Footwear & Accessories industry mean.
  • A Net Profit Margin of -69.9% means that ₩-0.70 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of InBioGen Co Ltd:

  • The MRQ is -69.9%. The company is making a huge loss. -2
  • The TTM is 221.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-69.9%TTM221.9%-291.8%
TTM221.9%YOY-782.5%+1,004.4%
TTM221.9%5Y-41.5%+263.5%
5Y-41.5%10Y-31.3%-10.3%
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ-69.9%3.5%-73.4%
TTM221.9%3.9%+218.0%
YOY-782.5%3.5%-786.0%
5Y-41.5%2.4%-43.9%
10Y-31.3%3.7%-35.0%
1.1.2. Return on Assets

Shows how efficient Inbiogen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Inbiogen to the Footwear & Accessories industry mean.
  • -0.4% Return on Assets means that Inbiogen generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of InBioGen Co Ltd:

  • The MRQ is -0.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 3.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-0.4%TTM3.2%-3.6%
TTM3.2%YOY-13.5%+16.7%
TTM3.2%5Y-2.4%+5.7%
5Y-2.4%10Y-1.7%-0.8%
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.4%2.0%-2.4%
TTM3.2%2.2%+1.0%
YOY-13.5%1.5%-15.0%
5Y-2.4%1.4%-3.8%
10Y-1.7%1.8%-3.5%
1.1.3. Return on Equity

Shows how efficient Inbiogen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Inbiogen to the Footwear & Accessories industry mean.
  • -0.4% Return on Equity means Inbiogen generated ₩0.00 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of InBioGen Co Ltd:

  • The MRQ is -0.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 3.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.4%TTM3.8%-4.1%
TTM3.8%YOY-32.9%+36.7%
TTM3.8%5Y-7.5%+11.3%
5Y-7.5%10Y-5.5%-2.0%
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.4%3.5%-3.9%
TTM3.8%3.7%+0.1%
YOY-32.9%3.5%-36.4%
5Y-7.5%2.4%-9.9%
10Y-5.5%3.7%-9.2%

1.2. Operating Efficiency of InBioGen Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Inbiogen is operating .

  • Measures how much profit Inbiogen makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Inbiogen to the Footwear & Accessories industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of InBioGen Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-17.4%+17.4%
TTM-17.4%YOY-54.2%+36.8%
TTM-17.4%5Y-13.5%-3.9%
5Y-13.5%10Y-13.0%-0.6%
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.8%-7.8%
TTM-17.4%5.9%-23.3%
YOY-54.2%4.5%-58.7%
5Y-13.5%4.0%-17.5%
10Y-13.0%5.0%-18.0%
1.2.2. Operating Ratio

Measures how efficient Inbiogen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Footwear & Accessories industry mean).
  • An Operation Ratio of 3.88 means that the operating costs are ₩3.88 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of InBioGen Co Ltd:

  • The MRQ is 3.882. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.724. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.882TTM2.724+1.158
TTM2.724YOY1.961+0.762
TTM2.7245Y2.240+0.484
5Y2.24010Y2.173+0.067
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8821.436+2.446
TTM2.7241.436+1.288
YOY1.9611.455+0.506
5Y2.2401.392+0.848
10Y2.1731.248+0.925

1.3. Liquidity of InBioGen Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Inbiogen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Footwear & Accessories industry mean).
  • A Current Ratio of 5.48 means the company has ₩5.48 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of InBioGen Co Ltd:

  • The MRQ is 5.476. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.493. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.476TTM4.493+0.983
TTM4.493YOY2.040+2.453
TTM4.4935Y3.161+1.332
5Y3.16110Y6.329-3.168
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4761.875+3.601
TTM4.4931.908+2.585
YOY2.0401.892+0.148
5Y3.1611.800+1.361
10Y6.3291.948+4.381
1.3.2. Quick Ratio

Measures if Inbiogen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Inbiogen to the Footwear & Accessories industry mean.
  • A Quick Ratio of 1.98 means the company can pay off ₩1.98 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of InBioGen Co Ltd:

  • The MRQ is 1.978. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.554. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.978TTM1.554+0.424
TTM1.554YOY0.616+0.938
TTM1.5545Y1.778-0.224
5Y1.77810Y2.492-0.715
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9780.825+1.153
TTM1.5540.826+0.728
YOY0.6160.844-0.228
5Y1.7780.880+0.898
10Y2.4920.893+1.599

1.4. Solvency of InBioGen Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Inbiogen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Inbiogen to Footwear & Accessories industry mean.
  • A Debt to Asset Ratio of 0.02 means that Inbiogen assets are financed with 1.7% credit (debt) and the remaining percentage (100% - 1.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of InBioGen Co Ltd:

  • The MRQ is 0.017. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.061. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.017TTM0.061-0.044
TTM0.061YOY0.486-0.425
TTM0.0615Y0.314-0.253
5Y0.31410Y0.282+0.032
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0170.445-0.428
TTM0.0610.444-0.383
YOY0.4860.495-0.009
5Y0.3140.472-0.158
10Y0.2820.443-0.161
1.4.2. Debt to Equity Ratio

Measures if Inbiogen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Inbiogen to the Footwear & Accessories industry mean.
  • A Debt to Equity ratio of 1.8% means that company has ₩0.02 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of InBioGen Co Ltd:

  • The MRQ is 0.018. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.071. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.018TTM0.071-0.053
TTM0.071YOY1.107-1.037
TTM0.0715Y0.606-0.535
5Y0.60610Y0.527+0.079
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0180.783-0.765
TTM0.0710.777-0.706
YOY1.1070.962+0.145
5Y0.6060.929-0.323
10Y0.5270.840-0.313

2. Market Valuation of InBioGen Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Inbiogen generates.

  • Above 15 is considered overpriced but always compare Inbiogen to the Footwear & Accessories industry mean.
  • A PE ratio of -41.45 means the investor is paying ₩-41.45 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of InBioGen Co Ltd:

  • The EOD is -41.451. Based on the earnings, the company is expensive. -2
  • The MRQ is -41.451. Based on the earnings, the company is expensive. -2
  • The TTM is -3.071. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-41.451MRQ-41.4510.000
MRQ-41.451TTM-3.071-38.380
TTM-3.071YOY-0.020-3.051
TTM-3.0715Y-0.642-2.429
5Y-0.64210Y-2.018+1.375
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
EOD-41.4518.488-49.939
MRQ-41.4517.872-49.323
TTM-3.0719.702-12.773
YOY-0.02011.289-11.309
5Y-0.64213.875-14.517
10Y-2.01815.874-17.892
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of InBioGen Co Ltd:

  • The EOD is -2,470.083. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2,470.083. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -634.010. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2,470.083MRQ-2,470.0830.000
MRQ-2,470.083TTM-634.010-1,836.073
TTM-634.010YOY-0.860-633.150
TTM-634.0105Y-126.845-507.165
5Y-126.84510Y-87.415-39.430
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
EOD-2,470.0834.266-2,474.349
MRQ-2,470.0834.269-2,474.352
TTM-634.0103.200-637.210
YOY-0.8601.744-2.604
5Y-126.8451.767-128.612
10Y-87.4153.467-90.882
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Inbiogen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Footwear & Accessories industry mean).
  • A PB ratio of 0.63 means the investor is paying ₩0.63 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of InBioGen Co Ltd:

  • The EOD is 0.627. Based on the equity, the company is cheap. +2
  • The MRQ is 0.627. Based on the equity, the company is cheap. +2
  • The TTM is 0.322. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.627MRQ0.6270.000
MRQ0.627TTM0.322+0.306
TTM0.322YOY0.063+0.259
TTM0.3225Y0.600-0.278
5Y0.60010Y0.503+0.097
Compared to industry (Footwear & Accessories)
PeriodCompanyIndustry (mean)+/- 
EOD0.6271.387-0.760
MRQ0.6271.408-0.781
TTM0.3221.382-1.060
YOY0.0631.569-1.506
5Y0.6001.512-0.912
10Y0.5031.828-1.325
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of InBioGen Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---34.9193536.108-101%-663.608+1800%696.610-105%513.488-107%
Book Value Per Share--14891.16310624.590+40%1337.124+1014%3245.465+359%2397.408+521%
Current Ratio--5.4764.493+22%2.040+168%3.161+73%6.329-13%
Debt To Asset Ratio--0.0170.061-72%0.486-96%0.314-94%0.282-94%
Debt To Equity Ratio--0.0180.071-75%1.107-98%0.606-97%0.527-97%
Dividend Per Share----0%-0%-0%-0%
Eps---56.332117.359-148%-616.171+994%-68.187+21%-47.989-15%
Free Cash Flow Per Share---0.945-23.005+2334%-33.492+3443%-31.358+3217%-27.343+2792%
Free Cash Flow To Equity Per Share---0.945-65.781+6859%26.679-104%112.327-101%115.762-101%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3471.002--------
Intrinsic Value_10Y_min--2830.563--------
Intrinsic Value_1Y_max---67.196--------
Intrinsic Value_1Y_min---66.247--------
Intrinsic Value_3Y_max--114.393--------
Intrinsic Value_3Y_min--102.823--------
Intrinsic Value_5Y_max--677.302--------
Intrinsic Value_5Y_min--601.432--------
Market Cap93257751800.0000%93257770480.00047853674564.238+95%5224612675.250+1685%39614298010.273+135%28318983433.809+229%
Net Profit Margin---0.6992.219-132%-7.825+1019%-0.415-41%-0.313-55%
Operating Margin----0.1740%-0.5420%-0.1350%-0.1300%
Operating Ratio--3.8822.724+43%1.961+98%2.240+73%2.173+79%
Pb Ratio0.6270%0.6270.322+95%0.063+896%0.600+5%0.503+25%
Pe Ratio-41.4510%-41.451-3.071-93%-0.020-100%-0.642-98%-2.018-95%
Price Per Share9340.0000%9340.0004681.675+100%83.625+11069%1065.148+777%778.645+1100%
Price To Free Cash Flow Ratio-2470.0830%-2470.083-634.010-74%-0.860-100%-126.845-95%-87.415-96%
Price To Total Gains Ratio-267.4760%-267.476-66.704-75%-0.209-100%-14.156-95%-13.582-95%
Quick Ratio--1.9781.554+27%0.616+221%1.778+11%2.492-21%
Return On Assets---0.0040.032-112%-0.135+3538%-0.024+555%-0.017+347%
Return On Equity---0.0040.038-110%-0.329+8602%-0.075+1888%-0.055+1355%
Total Gains Per Share---34.9193536.108-101%-663.608+1800%696.610-105%513.488-107%
Usd Book Value--104079408.64398926538.858+5%60423881.096+72%62598611.122+66%45699014.795+128%
Usd Book Value Change Per Share---0.0242.475-101%-0.465+1800%0.488-105%0.359-107%
Usd Book Value Per Share--10.4247.437+40%0.936+1014%2.272+359%1.678+521%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.0390.082-148%-0.431+994%-0.048+21%-0.034-15%
Usd Free Cash Flow---6607.111-241788.267+3560%-2071267.524+31249%-1271259.852+19141%-966262.556+14525%
Usd Free Cash Flow Per Share---0.001-0.016+2334%-0.023+3443%-0.022+3217%-0.019+2792%
Usd Free Cash Flow To Equity Per Share---0.001-0.046+6859%0.019-104%0.079-101%0.081-101%
Usd Market Cap65280426.2600%65280439.33633497572.195+95%3657228.873+1685%27730008.607+135%19823288.404+229%
Usd Price Per Share6.5380%6.5383.277+100%0.059+11069%0.746+777%0.545+1100%
Usd Profit---393723.6803299984.601-112%-17978505.517+4466%-759708.462+93%-535529.768+36%
Usd Revenue--563059.6861092140.824-48%1995652.831-72%1684839.331-67%1568598.424-64%
Usd Total Gains Per Share---0.0242.475-101%-0.465+1800%0.488-105%0.359-107%
 EOD+0 -2MRQTTM+17 -15YOY+25 -75Y+20 -1210Y+16 -16

3.2. Fundamental Score

Let's check the fundamental score of InBioGen Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-41.451
Price to Book Ratio (EOD)Between0-10.627
Net Profit Margin (MRQ)Greater than0-0.699
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.978
Current Ratio (MRQ)Greater than15.476
Debt to Asset Ratio (MRQ)Less than10.017
Debt to Equity Ratio (MRQ)Less than10.018
Return on Equity (MRQ)Greater than0.15-0.004
Return on Assets (MRQ)Greater than0.05-0.004
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of InBioGen Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5099.999
Ma 20Greater thanMa 509,340.000
Ma 50Greater thanMa 1009,340.000
Ma 100Greater thanMa 2009,340.000
OpenGreater thanClose9,340.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  14,893,757-512,50414,381,253-9,564,8214,816,432-3,433,3881,383,044-2,592,019-1,208,975
Net Income  14,893,757-512,50414,381,253-10,150,3694,230,884-3,423,504807,380-1,369,842-562,462
Gross Profit  259,365329,681589,045-4,306584,739-190,014394,725-687,054-292,329
Net Income from Continuing Operations  14,893,757-512,50414,381,253-10,150,3694,230,884-3,423,504807,380-855,143-47,763



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets151,305,409
Total Liabilities2,620,540
Total Stockholder Equity148,684,869
 As reported
Total Liabilities 2,620,540
Total Stockholder Equity+ 148,684,869
Total Assets = 151,305,409

Assets

Total Assets151,305,409
Total Current Assets11,575,982
Long-term Assets139,729,427
Total Current Assets
Cash And Cash Equivalents 6,088,915
Net Receivables 4,182,161
Inventory 876,604
Other Current Assets 315,850
Total Current Assets  (as reported)11,575,982
Total Current Assets  (calculated)11,463,530
+/- 112,452
Long-term Assets
Property Plant Equipment 2,594,742
Intangible Assets 649,377
Long-term Assets Other 0
Long-term Assets  (as reported)139,729,427
Long-term Assets  (calculated)3,244,120
+/- 136,485,307

Liabilities & Shareholders' Equity

Total Current Liabilities2,114,008
Long-term Liabilities506,532
Total Stockholder Equity148,684,869
Total Current Liabilities
Accounts payable 317,898
Other Current Liabilities 357,480
Total Current Liabilities  (as reported)2,114,008
Total Current Liabilities  (calculated)675,378
+/- 1,438,630
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt593,265
Long-term Liabilities  (as reported)506,532
Long-term Liabilities  (calculated)593,265
+/- 86,733
Total Stockholder Equity
Retained Earnings 8,949,943
Total Stockholder Equity (as reported)148,684,869
Total Stockholder Equity (calculated)8,949,943
+/- 139,734,926
Other
Capital Stock5,022,535
Common Stock Shares Outstanding 9,985
Net Invested Capital 148,684,442
Net Working Capital 9,461,974
Property Plant and Equipment Gross 4,808,441



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
12,375,563
11,947,245
15,277,804
14,031,020
13,389,537
13,025,672
12,619,785
12,799,005
24,320,788
60,960,595
76,645,695
76,838,683
90,919,390
84,010,228
85,115,366
87,389,424
96,881,140
136,613,685
123,681,571
137,143,909
274,474,964
235,374,620
162,476,969
123,805,196
141,814,848
144,303,228
152,238,103
153,196,819
151,305,409
151,305,409153,196,819152,238,103144,303,228141,814,848123,805,196162,476,969235,374,620274,474,964137,143,909123,681,571136,613,68596,881,14087,389,42485,115,36684,010,22890,919,39076,838,68376,645,69560,960,59524,320,78812,799,00512,619,78513,025,67213,389,53714,031,02015,277,80411,947,24512,375,563
   > Total Current Assets 
12,237,669
11,822,187
15,164,913
13,930,248
13,317,824
12,963,723
12,567,598
12,455,124
23,956,644
60,420,948
75,138,584
73,987,785
32,684,893
24,719,095
23,786,264
22,841,798
85,847,444
126,218,712
116,367,270
129,867,336
31,901,786
32,305,789
21,778,454
19,659,047
17,033,020
16,126,841
13,711,442
12,858,431
11,575,982
11,575,98212,858,43113,711,44216,126,84117,033,02019,659,04721,778,45432,305,78931,901,786129,867,336116,367,270126,218,71285,847,44422,841,79823,786,26424,719,09532,684,89373,987,78575,138,58460,420,94823,956,64412,455,12412,567,59812,963,72313,317,82413,930,24815,164,91311,822,18712,237,669
       Cash And Cash Equivalents 
435,286
895,814
5,234,495
5,204,809
251,268
395,401
508,176
1,199,864
617,292
211,835
17,367,329
17,892,666
8,042,414
19,548,969
17,523,947
14,794,119
9,114,103
8,025,555
28,419,308
31,595,563
23,151,711
13,536,901
10,759,198
8,308,920
9,289,571
8,710,626
6,627,863
6,241,688
6,088,915
6,088,9156,241,6886,627,8638,710,6269,289,5718,308,92010,759,19813,536,90123,151,71131,595,56328,419,3088,025,5559,114,10314,794,11917,523,94719,548,9698,042,41417,892,66617,367,329211,835617,2921,199,864508,176395,401251,2685,204,8095,234,495895,814435,286
       Short-term Investments 
0
0
0
0
4,309,148
3,007,723
259,000
7,318,117
0
57,236,967
45,000,000
50,000,000
20,000,000
0
0
1,491,000
69,920,441
111,447,995
79,891,469
88,283,030
0
0
0
0
0
0
0
0
0
00000000088,283,03079,891,469111,447,99569,920,4411,491,0000020,000,00050,000,00045,000,00057,236,96707,318,117259,0003,007,7234,309,1480000
       Net Receivables 
3,899,563
3,443,583
2,668,245
2,494,227
2,232,557
2,751,157
2,386,634
1,578,352
1,394,052
1,315,222
1,558,157
1,973,439
2,365,545
2,508,420
3,497,557
4,513,569
5,436,497
5,300,155
6,021,441
6,156,368
6,575,233
6,702,496
5,937,407
5,801,607
5,649,533
0
5,116,378
4,413,971
4,182,161
4,182,1614,413,9715,116,37805,649,5335,801,6075,937,4076,702,4966,575,2336,156,3686,021,4415,300,1555,436,4974,513,5693,497,5572,508,4202,365,5451,973,4391,558,1571,315,2221,394,0521,578,3522,386,6342,751,1572,232,5572,494,2272,668,2453,443,5833,899,563
       Inventory 
2,879,655
2,375,064
2,209,846
1,177,933
1,066,436
1,731,884
2,055,114
2,223,349
1,727,711
1,613,949
4,500,769
3,309,100
2,129,253
1,900,656
2,194,090
1,501,847
1,013,525
881,813
897,185
1,629,824
1,481,817
1,955,042
1,736,233
1,984,238
1,532,115
1,536,915
1,602,349
1,726,384
876,604
876,6041,726,3841,602,3491,536,9151,532,1151,984,2381,736,2331,955,0421,481,8171,629,824897,185881,8131,013,5251,501,8472,194,0901,900,6562,129,2533,309,1004,500,7691,613,9491,727,7112,223,3492,055,1141,731,8841,066,4361,177,9332,209,8462,375,0642,879,655
       Other Current Assets 
5,023,099
5,107,726
5,052,327
5,053,279
5,452,306
5,076,060
5,058,105
135,384
7,860
1
1
-1
145,375
742,384
540,217
518,266
308,440
488,185
1,030,975
2,121,245
609,843
10,007,529
3,280,966
3,496,054
518,497
353,423
337,395
326,737
315,850
315,850326,737337,395353,423518,4973,496,0543,280,96610,007,529609,8432,121,2451,030,975488,185308,440518,266540,217742,384145,375-1117,860135,3845,058,1055,076,0605,452,3065,053,2795,052,3275,107,7265,023,099
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
539,647
1,507,111
2,850,899
58,234,497
59,291,133
61,329,102
64,547,625
11,033,696
10,394,972
7,314,301
7,276,573
242,573,179
203,068,831
140,698,515
104,146,149
124,781,828
128,176,387
138,526,661
140,338,388
139,729,427
139,729,427140,338,388138,526,661128,176,387124,781,828104,146,149140,698,515203,068,831242,573,1797,276,5737,314,30110,394,97211,033,69664,547,62561,329,10259,291,13358,234,4972,850,8991,507,111539,647000000000
       Property Plant Equipment 
124,846
112,986
101,294
89,648
61,065
51,302
41,538
33,233
26,496
192,999
300,430
296,015
624,124
560,071
528,870
739,161
1,118,368
1,068,794
1,698,519
1,671,723
4,360,911
3,994,753
3,816,541
3,590,784
3,691,138
3,434,306
3,153,712
2,835,607
2,594,742
2,594,7422,835,6073,153,7123,434,3063,691,1383,590,7843,816,5413,994,7534,360,9111,671,7231,698,5191,068,7941,118,368739,161528,870560,071624,124296,015300,430192,99926,49633,23341,53851,30261,06589,648101,294112,986124,846
       Long Term Investments 
2,500
2,000
2,000
2,000
2,000
2,000
2,000
2,000
29,000
38,000
47,000
56,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000056,00047,00038,00029,0002,0002,0002,0002,0002,0002,0002,0002,500
       Intangible Assets 
1,900
1,425
950
475
0
0
0
0
0
0
0
10,889
122,704
126,498
115,181
214,435
535,874
507,777
482,339
472,076
462,589
451,435
591,281
551,127
510,973
470,819
430,665
390,511
649,377
649,377390,511430,665470,819510,973551,127591,281451,435462,589472,076482,339507,777535,874214,435115,181126,498122,70410,88900000004759501,4251,900
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
308,648
263,919
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000263,919308,648000000000
> Total Liabilities 
6,624,117
5,877,494
3,243,939
2,078,870
2,065,136
1,743,951
1,413,902
1,057,057
968,800
37,779,196
32,725,084
17,514,725
24,922,912
18,580,448
24,264,572
29,090,502
18,974,863
16,832,959
53,488,732
82,090,697
96,452,041
105,361,704
95,067,551
80,363,239
37,399,819
25,098,813
3,866,407
4,163,292
2,620,540
2,620,5404,163,2923,866,40725,098,81337,399,81980,363,23995,067,551105,361,70496,452,04182,090,69753,488,73216,832,95918,974,86329,090,50224,264,57218,580,44824,922,91217,514,72532,725,08437,779,196968,8001,057,0571,413,9021,743,9512,065,1362,078,8703,243,9395,877,4946,624,117
   > Total Current Liabilities 
5,869,283
5,122,291
2,491,076
1,321,208
1,317,297
1,054,377
770,596
543,134
636,380
37,375,138
32,191,588
16,883,455
24,302,643
17,934,282
23,751,529
28,411,827
18,132,844
16,019,111
17,075,041
35,592,199
27,843,177
33,260,351
21,524,925
11,527,169
3,809,586
24,159,963
2,317,031
2,175,588
2,114,008
2,114,0082,175,5882,317,03124,159,9633,809,58611,527,16921,524,92533,260,35127,843,17735,592,19917,075,04116,019,11118,132,84428,411,82723,751,52917,934,28224,302,64316,883,45532,191,58837,375,138636,380543,134770,5961,054,3771,317,2971,321,2082,491,0765,122,2915,869,283
       Short-term Debt 
2,571,193
2,201,541
1,496,798
357,877
357,877
407,877
407,877
0
0
37,000,000
7,047,922
8,179,267
9,521,748
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000009,521,7488,179,2677,047,92237,000,00000407,877407,877357,877357,8771,496,7982,201,5412,571,193
       Short Long Term Debt 
2,571,193
2,201,541
1,496,798
357,877
357,877
407,877
407,877
0
0
37,000,000
7,047,922
8,179,267
9,521,748
8,617,975
8,824,336
9,485,814
4,241,046
4,832,814
5,514,161
12,378,681
11,630,836
9,640,760
10,586,576
6,373,163
934,133
1,071,709
0
0
0
0001,071,709934,1336,373,16310,586,5769,640,76011,630,83612,378,6815,514,1614,832,8144,241,0469,485,8148,824,3368,617,9759,521,7488,179,2677,047,92237,000,00000407,877407,877357,877357,8771,496,7982,201,5412,571,193
       Accounts payable 
2,841,032
2,569,097
981,107
864,023
780,837
804,882
540,066
407,016
427,094
147,238
408,103
366,293
432,979
378,435
609,621
1,422,248
558,757
570,003
708,685
584,865
646,109
468,629
527,843
467,213
308,801
460,797
254,828
229,266
317,898
317,898229,266254,828460,797308,801467,213527,843468,629646,109584,865708,685570,003558,7571,422,248609,621378,435432,979366,293408,103147,238427,094407,016540,066804,882780,837864,023981,1072,569,0972,841,032
       Other Current Liabilities 
737,130
626,732
262,264
380,473
428,557
113,992
96,755
97,202
134,527
3,185
3,184
3,184
13,706,236
8,398,675
13,423,378
16,761,799
12,559,653
9,849,185
9,373,462
21,381,476
14,246,374
22,329,992
9,896,456
4,191,092
1,933,737
418,296
1,469,626
374,762
357,480
357,480374,7621,469,626418,2961,933,7374,191,0929,896,45622,329,99214,246,37421,381,4769,373,4629,849,18512,559,65316,761,79913,423,3788,398,67513,706,2363,1843,1843,185134,52797,20296,755113,992428,557380,473262,264626,732737,130
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
404,058
533,497
631,270
620,270
646,167
513,043
678,676
842,019
813,849
887,034
829,597
18,677,538
18,606,367
1,059,516
937,173
1,038,246
938,850
1,549,375
1,987,704
506,532
506,5321,987,7041,549,375938,8501,038,246937,1731,059,51618,606,36718,677,538829,597887,034813,849842,019678,676513,043646,167620,270631,270533,497404,058000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
174,004
266,274
249,886
357,947
201,847
147,247
358,912
530,026
512,269
1,161,030
948,806
1,779,202
1,551,333
638,372
544,080
840,161
811,823
740,522
667,680
593,265
593,265667,680740,522811,823840,161544,080638,3721,551,3331,779,202948,8061,161,030512,269530,026358,912147,247201,847357,947249,886266,274174,004000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
-1
11,500
59,500
119,000
182,100
256,100
350,400
398,050
437,000
463,000
463,400
582,950
570,950
569,950
514,100
484,987
347,662
268,954
217,388
176,957
176,957217,388268,954347,662484,987514,100569,950570,950582,950463,400463,000437,000398,050350,400256,100182,100119,00059,50011,500-1000000000
> Total Stockholder Equity
5,751,019
6,069,324
12,033,439
11,951,722
11,323,974
11,281,295
11,205,455
11,741,521
23,351,561
23,181,399
43,920,610
59,323,958
65,996,478
65,429,780
60,850,794
58,298,921
77,906,278
119,780,725
70,192,839
55,053,212
178,022,923
130,012,916
67,409,418
43,441,957
104,415,030
119,204,415
148,371,697
149,033,527
148,684,869
148,684,869149,033,527148,371,697119,204,415104,415,03043,441,95767,409,418130,012,916178,022,92355,053,21270,192,839119,780,72577,906,27858,298,92160,850,79465,429,78065,996,47859,323,95843,920,61023,181,39923,351,56111,741,52111,205,45511,281,29511,323,97411,951,72212,033,4396,069,3245,751,019
   Common Stock
10,013,641
10,146,832
11,820,606
11,820,606
11,820,606
11,820,606
11,820,606
11,820,606
14,497,981
14,497,981
16,830,796
16,830,796
19,830,796
19,830,796
20,622,232
21,003,184
25,780,699
25,780,698
25,780,699
25,780,699
26,698,410
26,698,410
26,698,410
26,698,410
70,442,592
0
100,442,167
0
0
00100,442,167070,442,59226,698,41026,698,41026,698,41026,698,41025,780,69925,780,69925,780,69825,780,69921,003,18420,622,23219,830,79619,830,79616,830,79616,830,79614,497,98114,497,98111,820,60611,820,60611,820,60611,820,60611,820,60611,820,60610,146,83210,013,641
   Retained Earnings Total Equity00000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
19,045,272
0
0
0
1
0
0
0
0
0
0
0
0
511,253
106,632
692,568
0
65,202
65,202
62,590
48,397
48,397
48,397
48,397
48,396
0
-4,607,075
0
0
00-4,607,075048,39648,39748,39748,39748,39762,59065,20265,2020692,568106,632511,25300000000100019,045,272



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue6,240,805
Cost of Revenue-4,964,624
Gross Profit1,276,1801,276,180
 
Operating Income (+$)
Gross Profit1,276,180
Operating Expense-12,435,483
Operating Income-6,194,679-11,159,303
 
Operating Expense (+$)
Research Development8,191
Selling General Administrative2,920,553
Selling And Marketing Expenses0
Operating Expense12,435,4832,928,744
 
Net Interest Income (+$)
Interest Income1,288,570
Interest Expense-262,145
Other Finance Cost-10,137,716
Net Interest Income11,164,141
 
Pretax Income (+$)
Operating Income-6,194,679
Net Interest Income11,164,141
Other Non-Operating Income Expenses0
Income Before Tax (EBT)19,371,754-6,194,679
EBIT - interestExpense = -262,145
18,857,055
19,119,200
Interest Expense262,145
Earnings Before Interest and Taxes (EBIT)019,633,899
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax19,371,754
Tax Provision-1,161,212
Net Income From Continuing Ops19,371,75418,210,542
Net Income18,857,055
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-11,164,141
 

Technical Analysis of Inbiogen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Inbiogen. The general trend of Inbiogen is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Inbiogen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of InBioGen Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 9,340 < 9,340 < 9,340.

The bearish price targets are: 9,340 > 9,340 > 9,340.

Tweet this
InBioGen Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of InBioGen Co Ltd. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

InBioGen Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of InBioGen Co Ltd. The current macd is 0.12636417.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Inbiogen price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Inbiogen. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Inbiogen price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
InBioGen Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartInBioGen Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of InBioGen Co Ltd. The current adx is 100.00.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Inbiogen shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
InBioGen Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of InBioGen Co Ltd. The current sar is 9,314.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
InBioGen Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of InBioGen Co Ltd. The current rsi is 100.00. The current phase is Overbought in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -1/(-13 +13).

  • Overbought in bear market: Short-term excessive buying, potential for relief decline. Consider shorting, be cautious of potential pullback. -1
InBioGen Co Ltd Daily Relative Strength Index (RSI) ChartInBioGen Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of InBioGen Co Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Inbiogen price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
InBioGen Co Ltd Daily Stochastic Oscillator ChartInBioGen Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of InBioGen Co Ltd. The current cci is 0.

InBioGen Co Ltd Daily Commodity Channel Index (CCI) ChartInBioGen Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of InBioGen Co Ltd. The current cmo is 100.00.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
InBioGen Co Ltd Daily Chande Momentum Oscillator (CMO) ChartInBioGen Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of InBioGen Co Ltd. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
InBioGen Co Ltd Daily Williams %R ChartInBioGen Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of InBioGen Co Ltd.

InBioGen Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of InBioGen Co Ltd. The current atr is 0.01470133.

InBioGen Co Ltd Daily Average True Range (ATR) ChartInBioGen Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of InBioGen Co Ltd. The current obv is 29,310,719.

InBioGen Co Ltd Daily On-Balance Volume (OBV) ChartInBioGen Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of InBioGen Co Ltd. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
InBioGen Co Ltd Daily Money Flow Index (MFI) ChartInBioGen Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for InBioGen Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal

6.3. Candlestick Patterns

InBioGen Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of InBioGen Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5099.999
Ma 20Greater thanMa 509,340.000
Ma 50Greater thanMa 1009,340.000
Ma 100Greater thanMa 2009,340.000
OpenGreater thanClose9,340.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Inbiogen with someone you think should read this too:
  • Are you bullish or bearish on Inbiogen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Inbiogen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about InBioGen Co Ltd

I send you an email if I find something interesting about InBioGen Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about InBioGen Co Ltd.

Receive notifications about InBioGen Co Ltd in your mailbox!